Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAZMINE study of zanidatamab + tucatinib + chemotherapy in HER2-positive advanced breast cancer
2025-524613-89-00Phase 2Authorised
- Sponsor
- MEDSIR
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zanidatamab, tucatinib, capecitabine and eribulin in breast cancer (4 arms), sponsored by MEDSIR. Primary endpoints: Maximum tolerated dose and recommended phase II dose for Cohort A, Maximum tolerated dose and recommended phase II dose for Cohort B and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
zanidatamabtucatinibcapecitabineeribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-524613-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524613-89-00.